Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia Sergina(University of California, San Francisco), Megan Rausch(University of California, San Francisco), Donghui Wang(University of California, San Francisco), Jimmy A. Blair(University of California, San Francisco), Byron Hann(University of California, San Francisco), Kevan M. Shokat(Cellular Research (United States)), Mark M. Moasser(University of California, San Francisco)
Cited by 986Open Access
Abstract
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al.|New England Journal of Medicine|2002|2k